Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations.
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsDrug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsThe metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes.Arrhythmogenic mechanisms of non-sedating antihistamines.Cardiovascular profile of loratadine.The metabolic profile of second-generation antihistamines.Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycinNext generation antihistamines: therapeutic rationale, accomplishments and advances.Emerging safety issues regarding long-term usage of H(1)receptor antagonists.Therapeutic advantages of third generation antihistamines.Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration.Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine.Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice.
P2860
Q24631021-29B80CDD-6EB9-4BBE-9449-CFAAB6644C1EQ28071256-EAC559E2-6868-4163-94C2-0C5272CF1E6CQ33709784-56134588-085B-4B38-BAC6-106CF211E91BQ33709818-40E9E180-6121-4265-9C4F-13058A707EFEQ33709830-BD82D485-E4B5-4B12-9BED-E473B7B22A5BQ33963369-E7E5F2C2-9E63-4AF8-BA43-66EB6F4DD01BQ34049823-8A07B92D-3B06-4A5D-BE7F-CB0619A0F397Q34660867-B77C9196-FE12-40AB-A700-B4BAB6FE0F80Q35194475-6E828FB9-E86B-41B1-8881-4B97419D2665Q39365138-2D8047A3-A0F3-448D-9530-7336CFFCB15CQ39558497-14A5A5D7-2E7A-47D0-B592-6365E26AFA66Q41612740-13302936-E50A-423F-9F84-C5F9565FB9BDQ45342956-D2A46491-CE54-4703-8781-B3FDEF05C886
P2860
Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations.
description
1995 nî lūn-bûn
@nan
1995 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Loratadine administered concom ...... ctrocardiographic evaluations.
@ast
Loratadine administered concom ...... ctrocardiographic evaluations.
@en
type
label
Loratadine administered concom ...... ctrocardiographic evaluations.
@ast
Loratadine administered concom ...... ctrocardiographic evaluations.
@en
prefLabel
Loratadine administered concom ...... ctrocardiographic evaluations.
@ast
Loratadine administered concom ...... ctrocardiographic evaluations.
@en
P2093
P2860
P1476
Loratadine administered concom ...... ctrocardiographic evaluations.
@en
P2093
Affrime MB
Brannan MD
Radwanski E
Reidenberg P
P2860
P304
P356
10.1016/0009-9236(95)90243-0
P407
P577
1995-09-01T00:00:00Z